ResearchIn-Press PreviewImmunologyInflammation
Open Access | 10.1172/jci.insight.185581
1Graduate Program in Immunology, Tufts Graduate School of Biomedical Sciences, Boston, United States of America
2Department of Immunology, Tufts University School of Medicine, Boston, United States of America
Find articles by Colson, T. in: PubMed | Google Scholar
1Graduate Program in Immunology, Tufts Graduate School of Biomedical Sciences, Boston, United States of America
2Department of Immunology, Tufts University School of Medicine, Boston, United States of America
Find articles by Cameron, J. in: PubMed | Google Scholar
1Graduate Program in Immunology, Tufts Graduate School of Biomedical Sciences, Boston, United States of America
2Department of Immunology, Tufts University School of Medicine, Boston, United States of America
Find articles by Muendlein, H. in: PubMed | Google Scholar
1Graduate Program in Immunology, Tufts Graduate School of Biomedical Sciences, Boston, United States of America
2Department of Immunology, Tufts University School of Medicine, Boston, United States of America
Find articles by Nolan, M. in: PubMed | Google Scholar
1Graduate Program in Immunology, Tufts Graduate School of Biomedical Sciences, Boston, United States of America
2Department of Immunology, Tufts University School of Medicine, Boston, United States of America
Find articles by Leiriao, J. in: PubMed | Google Scholar
1Graduate Program in Immunology, Tufts Graduate School of Biomedical Sciences, Boston, United States of America
2Department of Immunology, Tufts University School of Medicine, Boston, United States of America
Find articles by Kim, J. in: PubMed | Google Scholar
1Graduate Program in Immunology, Tufts Graduate School of Biomedical Sciences, Boston, United States of America
2Department of Immunology, Tufts University School of Medicine, Boston, United States of America
Find articles by Poltorak, A. in: PubMed | Google Scholar
1Graduate Program in Immunology, Tufts Graduate School of Biomedical Sciences, Boston, United States of America
2Department of Immunology, Tufts University School of Medicine, Boston, United States of America
Find articles by Li, X. in: PubMed | Google Scholar
Published July 31, 2025 - More info
Reprogramming autoreactive CD4⁺ effector T (Teff) cells into immunosuppressive regulatory T (Treg) cells represents a promising strategy for treating established autoimmune diseases. However, the stability and function of such reprogrammed Tregs under inflammatory conditions remain unclear. Here, we show that epigenetic activation of core Treg identity genes in Teff cells yields lineage-stable Effector T cell Reprogrammed Tregs (ER-Tregs). A single adoptive transfer of ER-Tregs not only prevents autoimmune neuroinflammation in mice when given before disease onset but also arrests its progression when administered after onset. Compared to Foxp3 overexpressing Teff cells, induced Tregs from naïve precursors, and endogenous Tregs, ER Tregs provide superior protection against autoimmune neuroinflammation. This enhanced efficacy stems from their inherited autoantigen specificity and selectively preserved effector cell transcriptional programs, which together bolster their fitness in inflammatory environments and enhance their suppressive capacity. Our results establish epigenetic reprogramming of autoreactive Teff cells as an effective approach to generate potent, stable Tregs for the treatment of refractory autoimmune conditions.